See more : Peña Verde, S.A.B. (PV.MX) Income Statement Analysis – Financial Results
Complete financial analysis of 2seventy bio, Inc. (TSVT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 2seventy bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Huaan Securities Co., Ltd. (600909.SS) Income Statement Analysis – Financial Results
- Newborn Town Inc. (9911.HK) Income Statement Analysis – Financial Results
- AMB Financial Corp. (AMFC) Income Statement Analysis – Financial Results
- Monster Arts, Inc. (APPZ) Income Statement Analysis – Financial Results
- Adlai Nortye Ltd. American Depositary Shares (ANL) Income Statement Analysis – Financial Results
2seventy bio, Inc. (TSVT)
About 2seventy bio, Inc.
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 100.39M | 91.50M | 54.52M | 248.12M | 44.30M | 54.58M |
| Cost of Revenue | 16.92M | 26.22M | 12.59M | 5.40M | 2.98M | 885.00K |
| Gross Profit | 83.47M | 65.28M | 41.93M | 242.73M | 41.32M | 53.69M |
| Gross Profit Ratio | 83.15% | 71.34% | 76.91% | 97.83% | 93.28% | 98.38% |
| Research & Development | 230.76M | 248.74M | 261.94M | 296.47M | 297.65M | 200.49M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 69.41M | 79.45M | 93.51M | 90.90M | 81.65M | 53.63M |
| Other Expenses | 20.91M | 6.06M | 21.65M | 18.06M | 20.13M | 19.16M |
| Operating Expenses | 321.08M | 328.19M | 355.44M | 387.36M | 379.29M | 254.12M |
| Cost & Expenses | 317.09M | 354.40M | 368.03M | 392.76M | 382.27M | 255.01M |
| Interest Income | 12.41M | 2.93M | 88.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.49M |
| Depreciation & Amortization | 10.29M | 11.53M | 16.40M | 13.19M | 12.59M | 13.35M |
| EBITDA | -206.42M | -251.38M | -297.16M | -131.45M | -329.19M | -187.08M |
| EBITDA Ratio | -205.62% | -274.49% | -574.21% | -45.70% | -728.37% | -307.66% |
| Operating Income | -216.70M | -262.91M | -313.51M | -144.64M | -337.97M | -203.43M |
| Operating Income Ratio | -215.87% | -287.34% | -575.01% | -58.29% | -762.99% | -372.72% |
| Total Other Income/Expenses | -867.00K | 8.76M | 21.30M | 24.52M | 17.38M | 3.68M |
| Income Before Tax | -217.57M | -254.15M | -292.21M | -120.11M | -320.59M | -199.75M |
| Income Before Tax Ratio | -216.73% | -277.77% | -535.95% | -48.41% | -723.75% | -365.98% |
| Income Tax Expense | 0.00 | -8.99K | -16.00M | 18.06M | 2.75M | 19.16M |
| Net Income | -217.57M | -254.14M | -276.21M | -138.17M | -323.34M | -199.75M |
| Net Income Ratio | -216.73% | -277.77% | -506.61% | -55.69% | -729.96% | -365.98% |
| EPS | -4.42 | -7.13 | -11.71 | -5.93 | -13.88 | -8.58 |
| EPS Diluted | -4.42 | -7.13 | -11.71 | -5.93 | -13.88 | -8.58 |
| Weighted Avg Shares Out | 49.28M | 35.64M | 23.59M | 23.29M | 23.29M | 23.29M |
| Weighted Avg Shares Out (Dil) | 49.28M | 35.64M | 23.59M | 23.29M | 23.29M | 23.29M |
Bronstein, Gewirtz & Grossman, LLC Encourages 2seventy bio, Inc. (TSVT) Stockholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESSWIRE / October 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 2seventy bio, Inc. ("2seventy bio" or "the Company") (NASDAQ:TSVT). Investors who purchased 2seventy bio securities are...
TSVT ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on Your 2seventy bio, Inc. investment
NEW YORK, NY / ACCESSWIRE / October 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of 2seventy bio, Inc. ("2seventy bio, Inc.") (NASDAQ:TSVT) concerning possible violations of federal securities laws. 2seventy bio issued a...
TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the Firm
NEW YORK , Oct. 7, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 2seventy bio, Inc. ("2seventy bio" or "the Company") (NASDAQ: TSVT). Investors who purchased 2seventy bio...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company")(NASDAQ:TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against 2seventy bio, Inc. (TSVT) And Encourages Stockholders to Reach Out
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 2seventy bio, Inc. ("2seventy bio" or "the Company") (NASDAQ:TSVT). Investors who purchased 2seventy bio securities are...
TSVT ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of 2seventy bio, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of 2seventy bio, Inc. ("2seventy bio, Inc.") (NASDAQ:TSVT) concerning possible violations of federal securities laws. 2seventy bio issued a...
Bronstein, Gewirtz & Grossman, LLC Is Investigating 2seventy bio, Inc. (TSVT) And Encourages Stockholders to Connect
NEW YORK, NY / ACCESSWIRE / October 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 2seventy bio, Inc. ("2seventy bio" or "the Company") (NASDAQ:TSVT). Investors who purchased 2seventy bio securities are...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
NEW YORK, NY / ACCESSWIRE / October 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company")(NASDAQ:TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
NEW YORK , Oct. 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") (NASDAQ: TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2seventy bio, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by 2seventy bio, Inc. (TSVT)
NEW YORK, NY / ACCESSWIRE / October 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of 2seventy bio, Inc. ("2seventy bio, Inc.") (NASDAQ:TSVT) concerning possible violations of federal securities laws. 2seventy bio issued a...
Source: https://incomestatements.info
Category: Stock Reports